title: Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
abstract: Progressive multifocal leukoencephalopathy is a rare but potentially lethal adverse event in natalizumab treated multiple sclerosis patients. We report on a 40-year old Caucasian man with typical relapsing progressive multiple sclerosis, who developed a reversible leukoencephalopathy syndrome after 43 natalizumab infusions mimicking progressive multifocal leukoencephalopathy. To our knowledge, this is the first case of its kind. Our case suggests that awareness ought to be sharpened for reversible leukoencephalopathy syndrome in the follow-up of natalizumab treated multiple sclerosis patients.
authors.affiliation: Department of Neurology at St Josef-Hospital, Ruhr-University Bochum, Germany. b.decard@klinikum-bochum.de
authors.forename: Bernhard F
authors.initials: BF
authors.lastname: Décard
authors.forename: Aiden
authors.initials: A
authors.lastname: Haghikia
authors.forename: Christina
authors.initials: C
authors.lastname: Tönnes
authors.forename: Jan
authors.initials: J
authors.lastname: Thöne
authors.forename: Carsten
authors.initials: C
authors.lastname: Lukas
authors.forename: Andrew
authors.initials: A
authors.lastname: Chan
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D001927:Brain Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000150:complications* / Q000188:drug therapy; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use; D011595:Psychomotor Agitation / Q000150:complications; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy; D013116:Spinal Cord / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000927:Anticonvulsants; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate